Carcinoma，Non-Small-Cell Lung
Conditions
Brief summary
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME.
Detailed description
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME (absorption, distribution, metabolism and excretion) trial and subsequent receiving AC0010 treatment.
Interventions
DRUGAC0010
Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
Sponsors
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* signed and dated informed consent * histologically or cytologically confirmed diagnosis of local advanced or recurrent NSCLC * failed to the treatment of EGFR-TKI and harbored T790M mutation * male, Age 18\ 65, have a body mass index (BMI)\>19 kg/m2 * Eastern Cooperative Oncology Group performance status(ECOG PS):0-1,Life expectancy of more than 3 months * main organs function is normal, laboratory values as listed below: blood test without blood transfusion within 14 days 1. Haemoglobin \>100 g/L 2. Absolute neutrophil count ≥2.0x10\^9/L or WBC ≥3.5 x10\^9/L 3. Platelet count ≥ 80x10\^9/L 4. Total bilirubin ≤1.5xULN 5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5 times upper limit of normal (ULN) 6. Serum creatinine ≤1.5xULN or creatinine clearance ratio ≥60 mL/ min * Any prior treatment (chemotherapy, radiotherapy or surgery) must be completed over 4 weeks(target therapy over 2 weeks) from the screening; Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03) * International normalized ratio (INR) ≤ 1.5 * Patients and their partners should be willing to use methods of contraception or total abstinence from start of dosing until 6 months after discontinuing of study treatment * Patients must withdraw from previous study of \[14C\] AC0010
Exclusion criteria
* Prior treated with AC0010 or allergic to drug or its formulation ingredients * Patients receiving other anti-tumor therapy * Impairment of GI disease, renal disorders or liver disease that may significantly alter the absorption and metabolic of AC0010 (e.g., Unable to swallow, liver, kidney or gastrointestinal partial resection, chronic diarrhea and intestinal obstruction) * HCVAb positive, active hepatitis B (excluding HBV carriers), Hepatitis virus markers positive and receiving anti-virus drugs * Meningeal metastasis; brain metastasis with whole brain radiotherapy; prior received hormones or mannitol for the brain metastasis * Previous EGFR-TKI treatment related Interstitial lung disease history * Known human immunodeficiency virus infection (HIV), other acquired or congenital immunodeficiency disease, or a history of organ transplantation * Any severe and / or uncontrolled active infections * Patients receiving concomitant immunosuppressive agents or high-dose corticosteroids * Any severe and / or uncontrolled medical conditions * Patients being treated with drugs recognized as being inhibitors or inducers of the liver isoenzyme in the last 4 weeks prior to registration in the current study * Within 3 days prior to the treatment taking of dragon fruit, pomelo, grapefruit, orange, mango and other fruit may affect drug metabolizing enzymes or juice * Major surgery, incisional biopsy or traumatic injuries; * Within 4 weeks prior to the screening patients with bleeding ≥ grade 3, non-healing wound, sever ulcer or bone fracture * Patients received high dose irradiation treatment or other 14C-labeled drug within 1 year * Known a history of alcoholism or drug abuse * Investigator judgment that patient is unsuitable to participate in study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months | To assess the overall Objective Response Rate(ORR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months | To assess the Progression Free Survival(PFS) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC. |
| Disease control rate | RECIST tumour assessments every 6 weeks from first dose until objective disease progression, up to approximately 11 months | To assess the Disease control rate(DCR) of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC. |
| Number of adverse events (AE) experienced by patients to assess safety | From date of Signed informed consent forms until 30 days after disease progression, intolerable toxicity or withdrawal from study, approximately up to 18 months) | To assess the safety of AC0010 in EGFR T790M mutation-positive patients with advanced NSCLC. |
Countries
China
Outcome results
None listed